YQ23 / New Beta Innovation - LARVOL DELTA

YAN: YQ23 Study in Patients With Critical Limb Ischaemia (clinicaltrials.gov) - P1/2 | N=5 | Terminated | Sponsor: New Beta Innovation Limited | Phase classification: P1b/2a ➔ P1/2 | N=51 ➔ 5 | Trial completion date: Jun 2024 ➔ Aug 2023 | Active, not recruiting ➔ Terminated; Due to business decision

Enrollment change • Phase classification • Trial completion date • Trial termination • Cardiovascular • Peripheral Arterial Disease

A Safety Study of YQ23 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: New Beta Innovation Limited | N=30 ➔ 3 | Trial completion date: Dec 2024 ➔ Jul 2023 | Active, not recruiting ➔ Terminated; Due to business decision

Enrollment change • Trial completion date • Trial termination • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

A Safety Study of YQ23 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: New Beta Innovation Limited | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Jun 2024

Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • TNNI3

YAN: YQ23 Study in Patients With Critical Limb Ischaemia (clinicaltrials.gov) - P1b/2a | N=51 | Recruiting | Sponsor: New Beta Innovation Limited | Active, not recruiting ➔ Recruiting | Trial completion date: Sep 2023 ➔ Jun 2024 | Trial primary completion date: May 2023 ➔ Dec 2023

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Peripheral Arterial Disease

YAN: YQ23 Study in Patients With Critical Limb Ischaemia (clinicaltrials.gov) - P1b/2a | N=51 | Active, not recruiting | Sponsor: New Beta Innovation Limited | Recruiting ➔ Active, not recruiting

Enrollment closed • Peripheral Arterial Disease

The anti-tumoral effects of the oxygen carrier YQ23 in a triple-negative breast cancer syngeneic model. (PubMed, Transl Cancer Res) - "In concordance with the weakened immunosuppression, the inflammatory cytokine interferon γ and cytolytic granzyme B were upregulated. YQ23 treatment may be a potential therapeutic strategy to modulate the TME in TNBC."

Journal • Breast Cancer • Immune Modulation • Inflammation • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • CD8 • GZMB • IFNG • PD-1

A Safety Study of YQ23 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: New Beta Innovation Limited; Trial completion date: Dec 2022 ➔ Dec 2023; Trial primary completion date: Dec 2021 ➔ Dec 2022

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • TNNI3

The Protective Effect of a Novel Cross-Linked Hemoglobin-Based Oxygen Carrier on Hypoxia Injury of Acute Mountain Sickness in Rabbits and Goats. (PubMed, Front Physiol) - "Besides, YQ23 exhibited no adverse effects on hemodynamics, myocardial ischemia, and renal injury. In conclusion, YQ23 effectively alleviates acute altitude hypoxia injury of AMS without aside effects."

Journal • Preclinical • Cardiovascular • Coronary Artery Disease • Hepatology • Liver Failure • Myocardial Ischemia • Renal Disease

A Safety Study of YQ23 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: New Beta Innovation Limited; Active, not recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • TNNI3

A Novel Cross-Linked Hemoglobin-Based Oxygen Carrier, YQ23, Extended the Golden Hour for Uncontrolled Hemorrhagic Shock in Rats and Miniature Pigs. (PubMed, Front Pharmacol) - " HBOC, such as YQ23, played vital roles in damage-control resuscitation for emergency care and benefited the uncontrolled hemorrhagic shock in the pre-hospital treatment by increasing oxygen delivery, reducing organ injury. Besides, HBOC could benefit the injured and trauma patients by extending the Golden Hour."

Journal • Preclinical • Hematological Disorders • Renal Disease

YAN: YQ23 Study in Patients With Critical Limb Ischaemia (clinicaltrials.gov) - P1b/2a; N=51; Recruiting; Sponsor: New Beta Innovation Limited; Not yet recruiting ➔ Recruiting

Enrollment open • Peripheral Arterial Disease

A Safety Study of YQ23 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1; N=30; Active, not recruiting; Sponsor: New Beta Innovation Limited; Recruiting ➔ Active, not recruiting

Clinical • Combination therapy • Enrollment closed • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • TNNI3

First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23 (clinicaltrials.gov) - P1; N=58; Completed; Sponsor: New Beta Innovation Limited; Active, not recruiting ➔ Completed

Clinical • Trial completion

First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23 (clinicaltrials.gov) - P1; N=58; Active, not recruiting; Sponsor: New Beta Innovation Limited; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Safety Study of YQ23 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: New Beta Innovation Limited; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • TNNI3

A Safety Study of YQ23 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1; N=30; Not yet recruiting; Sponsor: New Beta Innovation Limited

Clinical • Combination therapy • New P1 trial • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer